Skip to content

R&D at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$132.62M+159%
Exelixis logo
ExelixisEXEL
$199.92M-5.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$343.97M+67.2%
Incyte logo
IncyteINCY
$515.9M+18.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s R&D?
Nuvalent, Inc. (NUVL) reported R&D of $83.61M in Q1 2026.
How has Nuvalent, Inc.'s R&D changed year-over-year?
Nuvalent, Inc.'s R&D increased by 12.3% year-over-year, from $74.42M to $83.61M.
What is the long-term trend for Nuvalent, Inc.'s R&D?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s R&D has grown at a 71.4% compound annual growth rate (CAGR), from $35.56M to $306.97M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.